---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-149895"
form_type: "8-K"
ticker: null
cik: "0001845337"
company_name: "Day One Biopharmaceuticals, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:28:14.317700+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Day One sells Rare Pediatric Disease PRV for $108M; $8.1M to Viracta

## Summary
- Closed sale of Priority Review Voucher for $108M in cash on May 29, 2024.
- PRV awarded after FDA accelerated approval of OJEMDA (tovorafenib) on April 23, 2024.
- $8.1M of proceeds will be paid to Viracta to fully satisfy PRV-related obligations.
- Proceeds provide non-dilutive capital to fund OJEMDA launch and clinical development.

## SEC filing metadata
- accession: 0001193125-24-149895
- form_type: 8-K
- cik: 0001845337
- company_name: Day One Biopharmaceuticals, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/0001193125-24-149895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/d834662d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-149895
- JSON: https://secwatch.observer/filing/0001193125-24-149895.json
- Plain text: https://secwatch.observer/filing/0001193125-24-149895.txt

## Key facts
- M&A Transactions
  Day One Biopharmaceuticals, Inc. completed a disposition for $108.0 million (closed 2024-05-29).
  - Action: disposition
  - Consideration: $108.0 million
  - Closing: 2024-05-29
  source text: pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for $108.0 million, payable in cash, upon the closing of the sale, which occurred simultaneously with the parties entering into the PRV Transfer Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/0001193125-24-149895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.